The University of Louisville (UofL) Health in the US state of Kentucky has deployed a complete suite of Paige artificial intelligence (AI)-enabled digital pathology software in a bid to enhance cancer diagnosis services.
The move makes UofL Health one of the first health systems to adopt the US Food and Drug Administration (FDA)-approved Paige Prostate solution, which can be used for detecting cancer in prostate biopsies.
AI-based Paige Prostate has also received CE marking for use in laboratories and hospitals located in the European Economic Area.
As part of the collaboration, UofL Health will also use Paige’s digital pathology image viewer and case management tool, called FullFocus, as well as the breast cancer detection software known as Paige Breast.
Additionally, the health system will use Paige’s Software Development Kit. This offering enables the deployment of customised laboratory-developed tests for digital pathology as well as the use of AI algorithms to enhance operational efficiencies and image analysis.
Paige chief commercial officer Andy Moye said: “Completing our deployment at UofL Health is an exciting milestone for Paige as we help hospital systems adopt digital, AI-based technologies to make their existing workflows more accurate and efficient.
“We are proud to offer a robust portfolio of AI-enabled digital pathology technologies backed by the FDA.
“We are also excited to see how the UofL is utilising the Paige Software Development Kit to achieve near-term clinical impact, and we hope this will be the first of many research applications adopting our open technology to improve patient care.”
Founded in 2017, Paige focuses on delivering AI-based diagnostic software solutions.
Earlier this year, Quest Diagnostics partnered with Paige to develop software products that would facilitate pathologic diagnoses of cancer as well as various other diseases.